704 related articles for article (PubMed ID: 11083074)
1. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.
Wood GW; Holladay FP; Turner T; Wang YY; Chiga M
J Neurooncol; 2000 Jun; 48(2):113-20. PubMed ID: 11083074
[TBL] [Abstract][Full Text] [Related]
2. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.
Holladay FP; Heitz-Turner T; Bayer WL; Wood GW
J Neurooncol; 1996 Feb; 27(2):179-89. PubMed ID: 8699241
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
[TBL] [Abstract][Full Text] [Related]
6. Systemic T cell adoptive immunotherapy of malignant gliomas.
Plautz GE; Barnett GH; Miller DW; Cohen BH; Prayson RA; Krauss JC; Luciano M; Kangisser DB; Shu S
J Neurosurg; 1998 Jul; 89(1):42-51. PubMed ID: 9647171
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
8. Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.
Lim J; Park Y; Ahn JW; Sim J; Kang SJ; Hwang S; Chun J; Choi H; Kim SH; Chun DH; Sung KS; Kwack K; Cho K
PLoS One; 2021; 16(3):e0247293. PubMed ID: 33690665
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages.
Hus I; Kawiak J; Tabarkiewicz J; Radej S; Hoser G; Bojarska-Junak A; Schmitt M; Giannopoulos K; Dmoszynska A; Rolinski J
Oncol Rep; 2008 Aug; 20(2):443-51. PubMed ID: 18636210
[TBL] [Abstract][Full Text] [Related]
10. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
[TBL] [Abstract][Full Text] [Related]
12. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer.
Chang AE; Li Q; Jiang G; Teknos TN; Chepeha DB; Bradford CR
Head Neck; 2003 Mar; 25(3):198-209. PubMed ID: 12599287
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL
Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.
Quattrocchi KB; Miller CH; Cush S; Bernard SA; Dull ST; Smith M; Gudeman S; Varia MA
J Neurooncol; 1999; 45(2):141-57. PubMed ID: 10778730
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
17. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.
Ardon H; Van Gool S; Lopes IS; Maes W; Sciot R; Wilms G; Demaerel P; Bijttebier P; Claes L; Goffin J; Van Calenbergh F; De Vleeschouwer S
J Neurooncol; 2010 Sep; 99(2):261-72. PubMed ID: 20146084
[TBL] [Abstract][Full Text] [Related]
18. Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells.
Wenger A; Werlenius K; Hallner A; Thorén FB; Farahmand D; Tisell M; Smits A; Rydenhag B; Jakola AS; Carén H
Neoplasia; 2018 Jan; 20(1):25-31. PubMed ID: 29190492
[TBL] [Abstract][Full Text] [Related]
19. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
